PDAC patients who express high levels of IMP1 showed poor overall survival (OS, http://gepia.cancer-pku.cn/detail.php?gene=CDC25A###, accessed on 5 September 2023) and progression-free survival (PFS, http://gepia.cancer-pku.cn/detail.php?gene=CDC25A###, accessed on 5 September 2023) (Figure 1F,G), indicating that increased IMP1 in cancer tissue correlates with a poor prognosis in PDAC patients. This evidence concerns the gene IGF2BP1 and cancer.